These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 11044356)

  • 21. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
    Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Dopazo J; Rivas C; Benítez J
    Breast Cancer Res Treat; 2005 Mar; 90(1):5-14. PubMed ID: 15770521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
    Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
    Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women.
    Daidone MG; Luisi A; Martelli G; Benini E; Veneroni S; Tomasic G; De Palo G; Silvestrini R
    Br J Cancer; 2000 Jan; 82(2):270-7. PubMed ID: 10646876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
    Mirjolet JF; Barberi-Heyob M; Didelot C; Peyrat JP; Abecassis J; Millon R; Merlin JL
    Br J Cancer; 2000 Nov; 83(10):1380-6. PubMed ID: 11044365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases.
    Olopade OI; Adeyanju MO; Safa AR; Hagos F; Mick R; Thompson CB; Recant WM
    Cancer J Sci Am; 1997; 3(4):230-7. PubMed ID: 9263629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
    Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
    Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
    J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
    Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
    Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
    Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ
    Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
    Cass I; Holschneider C; Datta N; Barbuto D; Walts AE; Karlan BY
    Obstet Gynecol; 2005 Dec; 106(6):1327-34. PubMed ID: 16319259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
    Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
    Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulators of proliferation and apoptosis in carcinoma of the larynx.
    Whisler LC; Wood NB; Caldarelli DD; Hutchinson JC; Panje WR; Friedman M; Preisler HD; Leurgans S; Nowak J; Coon JS
    Laryngoscope; 1998 May; 108(5):630-8. PubMed ID: 9591537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
    Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
    Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer.
    Neri A; Marrelli D; Roviello F; DeMarco G; Mariani F; DeStefano A; Megha T; Caruso S; Corso G; Cioppa T; Pinto E
    Breast Cancer Res Treat; 2006 Sep; 99(1):77-83. PubMed ID: 16541314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers.
    Wikonkal NM; Berg RJ; van Haselen CW; Horkay I; Remenyik E; Begany A; Hunyadi J; van Vloten WA; de Gruijl FR
    Arch Dermatol; 1997 May; 133(5):599-602. PubMed ID: 9158413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HMGA1 protein expression in familial breast carcinoma patients.
    Chiappetta G; Ottaiano A; Vuttariello E; Monaco M; Galdiero F; Gallipoli A; Pilotti S; Jodice G; Siranoush M; Colombo M; Ripamonti CB; Pallante PL; Radice P; Fusco A
    Eur J Cancer; 2010 Jan; 46(2):332-9. PubMed ID: 19896837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers.
    Brimmell M; Burns JS; Munson P; McDonald L; O'Hare MJ; Lakhani SR; Packham G
    Br J Cancer; 1999 Nov; 81(6):1042-51. PubMed ID: 10576663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Correlation between apoptotic index, bcl-2 protein expression and progression and prognosis in breast carcinoma].
    Zhang GJ; Kimijima I; Watanabe T; Kanno M; Sagara H; Furukawa Y; Tsuchiya A; Abe R
    Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():415-21. PubMed ID: 9589045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.